T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab

T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab

Many adverse reactions associated with immune checkpoint inhibitor (ICI) treatments are immunologically driven and may necessitate discontinuation of the ICI. Herein, we present a patient who had been administered the radio contrast media amidotrizoate multiple times without issue but who then devel...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Munir Pirmohamed, Anna Olsson-Brown, Lorenzo Ressel, Sean Hammond, Joshua Gardner, Serat-E Ali, Paul Thomson, Carol Jolly, Dan Carr, Dean Naisbitt
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMJ Publishing Group 2021-05-01
Sarja:Journal for ImmunoTherapy of Cancer
Linkit:https://jitc.bmj.com/content/9/5/e002521.full

Internet

https://jitc.bmj.com/content/9/5/e002521.full

Samankaltaisia teoksia